Listed Funds Trust TrueShares Structured Outcome (January) ETF JANZ 深 滬
已收盤 09-05 16:00:00 美东时间
36.9694
-0.096
-0.26%
華盛通- 最 高37.02
- 今 開36.94
- 成交量 2493股
- 最 低 36.7914
- 昨 收 37.0654
- 總市值 2513.92万
- 52周最高 37.0654
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 30.07
- 委 比 0.00%
- 總股本 68.00万
- 歷史最高 37.0654
- 量 比 0.16
- 振 幅 0.62%
- 歷史最低 21.8202
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 guidance reaffirms strong growth outlook.
2024-11-08 01:39
Viatris nears 11-month high after Q3 beat
Viatris (NASDAQ:VTRS) shares reached the highest level since late February on Thursday after the maker of the anxiety drug Xanax reported better-than-expected financials for Q3 2024 and set its revenu...
2024-11-07 23:42
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.
2024-05-10 02:23
重药控股(000950.SZ)控股子公司获得药品注册证书
格隆汇5月5日丨重药控股(000950.SZ)发布公告，公司下属控股子公司重庆医药(集团)股份有限公司(以下简称“重药股份”)近日收到国家药品监督管理局核准签发...
2024-05-05 17:56
恒瑞医药(600276.SH)：SHR0302片药品上市许可申请
格隆汇8月26日丨恒瑞医药(600276.SH)公布，公司收到国家药品监督管理局下发的《受理通知书》，公司提交的SHR0302片药品上市许可申请，本品适用于非甾...
2023-08-26 14:54
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Fr...
2023-08-07 18:59
